tbuckley/cabot-search huggingface dataset:
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC).
Authors: Susanna Varkey Ulahannan, Ivor John Percent, Edward Arrowsmith, Maen A. Hussein, Viralkumar K. Bhanderi, John Hamm, Greg Andrew Durm, Damijan Erzen, Prasant Mohanty, David R. Spigel
Journal: Journal of Clinical Oncology (2022)

98 Background: Anti-PD-1 antibodies may have synergistic effects with other immunomodulatory or targeted agents. This open-label, Phase II platform trial is investigating ezabenlimab, an anti-PD-1 antibody, combined with other agents. Module C of the platform is assessing ezabenlimab plus BI 836880, a humanized bispecific nanobody targeting VEGF/Ang2. Pts are being enrolled into 5 advanced solid tumor cohorts: gastric/gastroesophageal adenocarcinoma; solid tumors (except non-squamous NSCLC or melanoma) with secondary resistance to anti-PD-(L)1 treatment (progression after at least SD for ≥4 months); solid tumors with primary resistance to anti-PD-(L)1 treatment; microsatellite stable (MSS) CRC; mismatch repair-proficient/MSS endometrial carcinoma. Here, we report data from the CRC cohort which has completed recruitment. Methods: Pts with locally advanced, unresectable or metastatic, MSS CRC were enrolled. Patients had received ≥1 line of prior systemic therapy for metastatic disease but were anti-PD-(L)-1 therapy-naïve. Prior anti-angiogenic therapy was permitted. Pts received BI 836880 720 mg plus ezabenlimab 240 mg iv q3w for 1 year or until disease progression, consent withdrawal or undue toxicity. Primary endpoint: investigator-assessed OR (CR or PR per RECIST v1.1). Secondary endpoints: duration of response, disease control, and PFS; safety is also being assessed. Results: 30 pts have been treated: 57% male; median age 61.5 years. All pts had received prior chemotherapy; most pts (23 [77%]) had received prior bevacizumab. At data cut-off (Sep 2021), median duration (range) of treatment was 115.5 (28–295) days; 6 pts remain on treatment. 1 (3%) pt (who had not received prior bevacizumab) achieved a confirmed PR; 16 (53%) pts had SD. Median duration (range) of SD was 128.5 (42–242) days. 29/17/2 (97/57/7%) pts had an AE (any/G3/G4). The most frequent AEs (any/G3) were nausea (40/10%), fatigue (30/3%), peripheral edema (30/0%), vomiting (27/7%), and hypertension (27/17%). There were two G4 AEs (hypertension; platelet count decreased) and no G5 AEs. 24/10/2 (80/33/7%) pts had a drug-related AE (any/G3/G4); most commonly (any/G3) nausea (33/7%), fatigue (27/3%) and hypertension (27/17%). 3 (10%) pts had an infusion-related reaction (G1, n = 1; G2, n = 2). 2 (7%) pts had an AE leading to discontinuation (G3 bile duct stone and G2 peripheral edema). Immune-related AEs were reported in 6 (20%) pts and serious AEs occurred in 13 (43%) pts. Conclusions: BI 836880 plus ezabenlimab had a manageable safety profile in pts with advanced MSS CRC; however, anti-tumor activity was limited in these pts, the majority of whom had received prior bevacizumab. Clinical trial information: NCT03697304.
Reduced pulmonary hypertension and right ventricular weight in mice treated with the angiotensin receptor blocker, Candesartan Hunter C. Champion, Trinity J. Bivalacqua, Luis Ortiz, Medel Reyes, Albert L. Hyman, Philip J. Kadowitz. Johns Hopkins Hospital, Baltimore, MD, Tulane University, New Orleans, LA
Journal: Journal of the American College of Cardiology (2001)
Association News
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy and toxicity of neoadjuvant immune checkpoint inhibitors in resectable gastric cancer: A meta-analysis and systematic review.
Authors: Song Li, Qian Xu, Xin Dai, Xue Zhang, Miao Huang, Kai Huang, Jian Wang, Jiahui Chu, Lian Liu
Journal: Journal of Clinical Oncology (2022)

291 Background: Immune checkpoint inhibitors (ICI) have made significant breakthroughs in late-stage gastric cancer. It is an attractive issue whether ICIs also function in the neoadjuvant setting. Methods: A systematic review was performed using combined terms related to “stomach cancer”, “gastric cancer”, “gastroesophageal cancer”, “immune checkpoint inhibitor”, “PD-1”, “PD-L1” and “neoadjuvant” in PubMed and annual meeting of ASCO, ASCO GI, ESMO, and ESMO GI from 2019 to 2021. Complete pathological response (CPR) rates, major pathological response (MPR) rates, R0 resection rates, and side effects were pooled and analyzed. MPR was defined as ≤10% viable tumor cells and included CPR. Study outcomes were pooled using the function METAPHOR in the META package in R.3.6.1. The I 2 and P statistics were used to evaluate heterogeneity among studies. Funnel plots were used for publication bias assessment. Results: A total of 13 phase I/II clinical trials, including 332 resectable gastric cancer (T2-4 or N+) patients with neoadjuvant ICI-containing treatments, were collected. The pooled rates of CPR, MPR, and R0 resection were 0.16 (95% credible intervals (CI), 0.12-0.22), 0.36 (95% CI, 0.24-0.51), and 0.97 (95% CI, 0.94-0.99), respectively. As a comparison, outcomes from 25 studies on neoadjuvant chemotherapy were also pooled, with rates of CPR 0.08 (95% CI, 0.06-0.11), MPR 0.22 (95% CI, 0.19-0.26), and R0 resection 0.84 (95% CI, 0.80-0.87). Besides, the overall grade 3 or higher toxicity rates were 0.24 (95% CI 0.03-0.54) vs. 0.28 (95% CI 0.13-0.47) in ICI-based treatment and chemotherapy groups. Stratified by treatment strategies, ICI alone showed the lowest efficacy (CPR 0.07, 95% CI 0.02-0.19 and MPR 0.16, 95% CI 0.03-0.29). Addition of chemotherapy to ICI promoted the CPR (0.15, 95% CI 0.10-0.22) and MPR (0.36, 95% CI 0.22-0.50). Further addition of radiotherapy displayed the highest CPR (0.35, 95% CI 0.21-0.52) and MPR (0.74, 95% CI 0.54-0.93). Only four trials reported the outcomes of dMMR/MSI-H patients, with superior CPR (0.39, 95% CI 0.20-0.62) and MPR (0.82, 95% CI 0.82-1.00), while those of pMMR/MSS patients were 0.05 (95% CI 0.00-0.13) and 0.20 (95% CI 0.20-0.31) respectively, among which 2 trials used ICI only. Conclusions: Neoadjuvant ICI plus chemotherapy/radiotherapy, instead of ICI alone, has better pathological responses and R0 resection rates than chemotherapy. dMMR/MSI-H is a superior biomarker for neoadjuvant ICI therapy for resectable gastric cancer. The value or biomarker of immunotherapy in pMMR/MSS patients remains exploring.[Table: see text]
Difamilast 软膏对日本儿童特应性皮炎的效果
Journal: British Journal of Dermatology (2022)

Abstract Linked Article: Saeki et al. Br J Dermatol 2022; 186:40–49. 特应性皮炎 (AD, 也称为“湿疹”) 是一种慢性皮肤病, 主要引起瘙痒和起泡。该疾病在儿童中最常见, 并有许多负面后果。外用治疗 (涂抹于皮肤) 是治疗 AD 的主要方法, 但效果有限。因此, 需要开发安全且有效的新治疗。Difamilast 是一种新的治疗, 作用于导致 AD 的炎症的重要部分。 在这项试验中, 我们旨在查明 Difamilast 软膏在改善日本 2 至 14 岁儿童 AD 皮疹方面是否优于非活性软膏基剂 (“赋形剂”) 。我们将 251 名轻度至中度 AD 儿童随机分为两组, 分别接受 Difamilast (强度为 0·3% 或 1%) 或赋形剂 (每日两次, 涂抹于受影响部位) 。然后, 我们使用一个众所周知的评分量表, 来评估每种软膏在治疗 1、2 和 4 周后是否成功改善皮疹。 治疗 4 周后, 我们发现根据评分标准, 接受 Difamilast 0·3% 或 Difamilast 1% 软膏的儿童中有 45–47% 治疗成功, 而接受赋形剂软膏的儿童中有 18% 治疗成功。与赋形剂相比, Difamilast 治疗也显著改善了一些令人烦恼的症状, 尤其是瘙痒, 通常在治疗开始后 1 周便出现改善。接受 Difamilast 治疗的儿童几乎没有副作用, 并且离开试验的人数少于接受赋形剂治疗的儿童。 综上所述, 本试验表明, Difamilast 可有效治疗日本儿童的 AD, 且耐受性良好。 Linked Article: Saeki et al. Br J Dermatol 2022; 186:40–49.
JAMA Reference Directories
Journal: JAMA (1976)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Text-Book of Inorganic Pharmaceutical Chemistry.
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Research brief
Authors: Dara Mohammadi
Journal: The Lancet Infectious Diseases (2016)

A new technique to monitor the movement of chickens might help to combat food poisoning. By using cameras to analyse chicken-flock behaviour, researchers at Oxford University have unearthed an early warning system that can identify flocks of chickens infected with campylobacter, the most common bacterial source of food poisoning in people in the UK, in chickens as young as 7–10 days. Current on-farm sampling methods, which take much longer, are in need of improvement—as much as 70% of chicken flocks in the European Union are campylobacter-positive at slaughter.
Reflecting on World Asthma Day in the era of COVID-19
Authors: None The Lancet Respiratory Medicine
Journal: The Lancet Respiratory Medicine (2020)

On May 2, 2020, World Asthma Day will again focus on the needs of people with asthma across the globe. Previous themes have included managing asthma and living with the disease. These themes resonate more than ever this year, as any discussions are likely to be dominated by current debates in relation to the coronavirus disease 2019 (COVID-19) pandemic and its effects on asthma care and management.
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study
Authors: Jasmeer P Chhatwal, Stephanie A Schultz, Eric McDade, Aaron P Schultz, Lei Liu, Bernard J Hanseeuw, Nelly Joseph-Mathurin, Rebecca Feldman, Colleen D Fitzpatrick, Kathryn P Sparks, Johannes Levin, Sarah B Berman, Alan E Renton, Bianca T Esposito, Maria Vitoria Fernandez, Yun Ju Sung, Jae Hong Lee, William E Klunk, Anna Hofmann, James M Noble, Neill Graff-Radford, Hiroshi Mori, Steven M Salloway, Colin L Masters, Ralph Martins, Celeste M Karch, Chengjie Xiong, Carlos Cruchaga, Richard J Perrin, Brian A Gordon, Tammie L S Benzinger, Nick C Fox, Peter R Schofield, Anne M Fagan, Alison M Goate, John C Morris, Randall J Bateman, Keith A Johnson, Reisa A Sperling
Journal: The Lancet Neurology (2022)
Editorial: Starting young.
Journal: BMJ (1973)

3female, but in male patients these clinical clues could have some diagnostic value.But ultimate diagnosis must depend on full investigation with electromyography, serum enzyme studies, and muscle biopsy.The distinction is important, because Duchenne mus- cular dystrophy is invariably a progressive and fatal disorder.In some patients with spinal muscular atrophy the disease may undergo temporary or even prolonged arrest, and often the prognosis is 'better than it is in cases of the Duchenne type.Furthermore, an accurate diagnosis is needed for genetic counselling, as the sisters of 'boys suffering from Duchenne dystrophy may possibly be carriers of the Xlinked gene, whereas unaffected sibs of a child with spinal muscular atrophy of autosomal recessive inheritance are un- likely to pass on the disease to their offspring unless they marry a blood relation.
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
Authors: Makoto Ueno, Chigusa Morizane, Masafumi Ikeda, Kentaro Sudo, Yoshinori Hirashima, Masataka Kuroda, Yuki Fukuyama, Takuji Okusaka, Junji Furuse
Journal: Journal of Clinical Oncology (2022)

553 Background: Although FOLFIRINOX and nab-paclitaxel plus gemcitabine have improved the survival of unresectable pancreatic cancer patients, high unmet medical needs still exist for the treatment of this cancer. Nivolumab has shown efficacy for multiple cancer types in not only its monotherapy but also combinations with conventional chemotherapies. This study aimed to assess the efficacy and safety of nivolumab in combination with modified FOLFIRINOX, which is one of the first line chemotherapy for pancreatic cancer. Methods: Thirty-one treatment-naïve patients with metastatic, unresectable/recurrent pancreatic cancer patients received nivolumab (480 mg, every 4 weeks) plus modified FOLFIRINOX (oxaliplatin 85 mg/m 2 , levofolinate 200 mg/m 2 , irinotecan 150 mg/m 2 and fluorouracil 2400 mg/m 2 , every 2 weeks). The primary endpoint was objective response rate (ORR) (central assessment). Secondary endpoints were overall survival (OS), progression-free survival (PFS) (central assessment), safety etc. Results: The median duration of follow-up was 13.40 months. ORR was 32.3% (CR: 0.0%, PR: 32.3%) and the median duration of response was 7.36 (range 3.5-20.1+) months. Median OS and PFS were 13.40 (90% CI 10.87-15.24) months and 7.39 (90% CI 3.88-7.59) months, respectively. The 1-year survival rate was 54.8 (90% CI 39.1-68.1) %. The most frequently reported grade 3-4 drug-related adverse events were neutrophil count decreased (38.7%), decreased appetite (16.1%), hypokalemia (12.9%), febrile neutropenia (9.7%), nausea (9.7%) and white blood cell count decreased (9.7%). Adrenal insufficiency (3.2%) was observed as immune mediated adverse event. Conclusions: Nivolumab in combination with modified FOLFIRINOX had a manageable safety profile in patients with metastatic pancreatic cancer. Additional work is needed to determine the population who can benefit from the combination. Clinical trial information: JapicCTI-184230.
Eosinophilic pustular folliculitis effectively treated with recombinant interferon-γ: suppression of mRNA expression of interleukin 5 in peripheral blood mononuclear cells
Authors: M. FUSHIMI, Y. TOKURA, Y. SACHI, H. HASHIZUME, H. SUDO, H. WAKITA, F. FURUKAWA, M. TAKIGAWA
Journal: British Journal of Dermatology (1996)
Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry
Authors: Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Werner Linkesch, Michael Pfeilstöcker, Eva Maria Autzinger, Christoph Tinchon, Thamer Sliwa, Alois Lang, Wolfgang R. Sperr, Dietmar Geissler, Peter Krippl, Daniela Voskova, Dieter H. Rossmann, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl-Spandl, Georg Theiler, Peter Valent, Otto Eckmüllner, Richard Greil
Journal: Blood (2014)
Racial differences in the use of invasive cardiac procedure and 1-year clinical outcomes for non-Q-wave myocardial infarction patients randomized to invasive vs. Conservative management Huma Samar, Prabhakara S. Heggunje, Prakash C. Deedwania, Michael J. Wade, Peter E. Carson, David R. Ferry, Robert A. O'Rourke, William E. Boden. Veterans Affairs Medical Center, Syracuse, NY, Hartford Hospital, Hartford, CT
Journal: Journal of the American College of Cardiology (2001)
Carvedilol
Authors: William H. Frishman
Journal: New England Journal of Medicine (1998)

Carvedilol is a β-adrenoreceptor–antagonist drug with α1-adrenoreceptor–antagonist activity. It was approved in the United States in September 1995 for the treatment of patients with essential hypertension and in May 1997, on the basis of the results of several clinical trials,18 became the first adrenoreceptor-blocking drug to receive approval for the treatment of symptomatic heart failure.Pharmacodynamic and Pharmacokinetic PropertiesCarvedilol is a racemic lipophilic aryloxypropanolamine (Figure 1) that causes both precapillary vasodilatation by means of α1-adrenoreceptor blockade and nonselective β-adrenoreceptor blockade and is devoid of intrinsic sympathomimetic activity.9 Its membrane-stabilizing activity is less than that . . .
Diagnosis and Classification of Diabetes Mellitus
Journal: Diabetes Care (2006)

OF DIABETES MELLITUS -Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels.Several pathogenic processes are involved in the development of diabetes.These range from autoimmune destruction of the ␤-cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action.The basis of the abnormalities in carbohydrate, fat, and protein metabolism in diabetes is deficient action of insulin on target tissues.Deficient insulin action results from inadequate insulin secretion and/or diminished tissue responses to insulin at one or more points in the complex pathways of hormone action.Impairment of insulin secretion and defects in insulin action frequently coexist in the same patient, and it is often unclear which abnormality, if either alone, is the primary cause of the hyperglycemia.Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision.Impairment of growth and susceptibility to certain infections may also accompany chronic hyperglycemia.Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia with ketoacidosis or the nonketotic hyperosmolar syndrome.Long-term complications of diabetes include retinopathy with potential loss of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot ulcers, amputations, and Charcot joints; and autonomic neuropathy causing gastrointes-
A national survey of Sudden Death Syndrome (SDS): Results from cardiological evaluation of first degree relatives Elijah R. Behr, Anne Casey, Ann O'Donoghue, Maurice Greenberg, Maureen Sheppard, Melissa Wright, Michael Davies, William J. McKenna, Tim Bowker, David Wood. St. George's Hospital Medical School, London, United Kingdom, Royal Brompton Hospital, National Heart &amp; Lung Institute, Imperial College School of Medicine, London, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
Assessment of changes in chest wall mechanics in esophageal cancer survivors using a 3D-motion capture system.
Authors: Karina Tukanova, Matthew Banger, George Hanna, Alison McGregor, Sheraz Markar
Journal: Journal of Clinical Oncology (2022)

TPS360 Background: Surgical resection remains the mainstay of treatment for loco-regional esophageal cancer. Traditional open esophagectomy is associated with considerable morbidity, with postoperative pulmonary complications (PPC) being the most frequently observed morbidity. There are several peri- and postoperative factors that are known to affect the respiratory mechanics, including an open surgical approach, administration of sedatives, rib spreading with subsequent fracture or nerve injury, presence of PPC and neuropathic pain leading to post-thoracotomy syndrome. Enhanced recovery programmes with early mobilization protocols and chest physiotherapy have been shown to reduce pulmonary complication rates. However, no data is currently available regarding the long-term respiratory function, quality of life and chest wall function in esophageal cancer survivors. Quantification of chest wall movements provides an objective measurement of function for the long term assessment of chest wall mechanics and could be used to develop tailored physiotherapy for patients undergoing esophagectomy. The aim of this study is to develop a method to objectively quantify changes in breathing mechanics in esophageal cancer survivors using a biomechanical approach. Methods: In the initial phase, an 89-marker protocol will be validated against a 3D-printed chest wall model that can produced simulate of normal and abnormal motions. Retroreflective markers will be placed non-invasively on the anterior, posterior, and lateral parts of the thorax and abdomen. A working protocol of breathing mechanics will be assessed in healthy control volunteers with the subject seated in upright position. Subjects will perform the respiratory function tests, the spirometer and the respiratory pressure meter. Further to this clinical assessment, the impact of thoracic movements and treadmill exercise will be assessed on the parameters obtained from changes in breathing movements. Following this, an optimization phase will refine markers placement and identify parameters that are most likely to be clinically relevant in the assessment of breathing mechanics. A finalized protocol will be trialled in esophageal cancer survivors, to identify changes in thoracoabdominal motion after surgery and to assess whether these changes are associated with impairment in health-related quality of life. This information will aid the development of evidenced based physiotherapy regimens tailored to the needs of this patient population. Clinical trial information: NCT03835273.